Recombinant activated factor VII: A new weapon in the fight against hemorrhage

Obstetrics and Gynecology

Volumn 101, Issue 6, 2003, Pages 1155-1156

  Branch, D Ware ^a   Rodgers, George M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LIVER ENZYME; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN;

ANTICOAGULATION; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG UTILIZATION; HEART INFARCTION; HEMOLYSIS; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; NONHUMAN; PILOT STUDY; POSTOPERATIVE HEMORRHAGE; POSTPARTUM HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; VON WILLEBRAND DISEASE;

EID: 0038209049     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(03)00365-X     Document Type: Editorial

References (18)

1. Hay C.R., Negrier C., Ludlam C.A. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa A multicentre study . Thromb Haemost. 78:1997;1463-1467.
2. Lusher J.M., Roberts H.R., Davignon G., Joist J.H., Smith H., Shapiro A., et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 4:1998;790-798.
3. ten Cate H., Bauer K.A., Levi M., Edgington T.S., Sublett R.D., Barzegar S., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 92:1993;1207-1212.
4. Lisman T., Moschatsis S., Adelmeijer J., Nieuwenhuis H.K., de Groot P.G. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIbbeta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 101:2003;1864-1870.
5. Bouwmeester F.W., Jonkhoff A.R., Verheijen R.H.M., van Geijn H.P. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol. 101:2003;1174-1176.
6. Daniłoś J., Goral A., Paluszkiewicz P., Przesmycki K., Kotarski J. Successful treatment with recombinant factor VIIa for intractable bleeding at pelvic surgery. Obstet Gynecol. 101:2003;1172-1173.
7. Friederich P.W., Henny C.P., Messelink E.J., Geerdink M.G., Keller T., Kurth K.H., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy A double-blind placebo-controlled randomised trial . Lancet. 361:2003;201-205.
8. Hendriks H.G., Meijer K., de Wolf J.T., Klompmaker I.J., Porte R.J., de Kam P.J., et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation A pilot study . Transplantation. 71:2001;402-405.
9. Jeroukhimov I., Jewelewiez D., Zaias J., Hensley G., MacLeod J., Cohn S.M., et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma. 53:2002;1053-1057.
10. Martinowitz U., Kenet G., Segal E., Luboshitz J., Lubetsky A., Ingerslev J., et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 51:2001;431-438.
11. Zupancic Salek S., Sokolic V., Viskovic T., Sanjug J., Simic M., Kastelan M. Successful use of recombinant factor VIIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol. 108:2002;162-163.
12. Friederich P.W., Wever P.C., Briet E., Doorenbos C.J., Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol. 66:2001;292-294.
13. Gerotziafas G.T., Zervas C., Gavrielidis G., Tokmaktsis A., Hatjiharissi E., Papaioannou M., et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol. 69:2002;219-222.
14. Berthier A.M., Guillygomarc'h A., Messner M., Pommereuil M., Bader G., De Mello G. Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients. Vox Sang. 82:2002;119-121.
15. Bijsterveld N.R., Moons A.H., Boekholdt S.M., van Aken B.E., Fennema H., Peters R.J., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 106:2002;2550-2554.
16. Deveras R.A., Kelssler C.M. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 137:2002;884-888.
17. Aledort L.M. rFVIIa - its thrombogenicity. Thromb Haemost. 84:2000;522-523.
18. Roberts H.R. Clinical experience with activated factor VII Focus on safety aspects . Blood Coagul Fibrinolysis. 9:(Suppl):1998;S115-S118.